Dr. Siwen Hu-Lieskovan is an Assistant Professor of Medicine on tenure track, and director of Solid Tumor Immunotherapy at the Huntsman Cancer Institute, University of Utah. She was recently recruited from UCLA, where she received her hematology/oncology fellowship and junior faculty training under the mentorship of Dr. Antoni Ribas. She is a board-certified oncologist with clinical focus on melanoma and early phase testing ofcancer immunotherapies in solid tumors. Dr. Hu-Lieskovan is Study Chair and Translational Lead of several trials initiated by the SWOG melanoma committee, and a consultant for pharmaceutical and biotechnology companies.
Her research focuses on the mechanisms of response and resistance to immunotherapies, and provides rationale for combination strategies, by studying immunecompetent (syngeneic) animal models and patient-derived clinical samples. She has authored/coauthored research articles, reviews, editorials and book chapters in peer-reviewed journals including Science Translational Medicine and the New England Journal of Medicine. She has numerous awards, including: American Society of Clinical Oncologist(ASCO) Young Investigator Award (YIA) and Career Development Award, Stand Up To Cancer(SU2C)/ American Association for Cancer Research (AACR) Sharp Award, Daniel VonHoff Innovative Protocol Award, ASCO Merit Award, and many more. She also serves as a co-chair of the SITC Biomarker Taskforce Resources and Useful Tool Subcommittee since 2018, and a co-chair of the academic committee of the Chinese-American Hematologist and Oncologist Network (CAHON) since 2016.